Feasibility of a Hospital-at-Home Program for Autologous Hematopoietic Stem Cell Transplantation

Autores de IDIVAL

• Soledad González Barreda

  Autor

• 

  Guillermo Martín Sánchez

  Autor

• Juan José Parra Jordan

  Autor

• 

  Sara Fernández Luis

  Autor

• Rocío Lobeira Rubio

  Autor

• 

  Lucrecia Yáñez San Segundo

  Autor

• Julio Baro Calle

  Autor

• Carlos Richard Espiga

  Autor

• 

  María Aránzazu Bermúdez Rodríguez

  Autor

• 

  Enrique María Ocio San Miguel

  Autor

• Pedro José Sanroma Mendizabal

  Autor

Autores ajenos al IDIVAL

• Calvo JA
• Manzano A
• Carrera C

Unidades

• 

  NEOPLASIAS HEMATOLÓGICAS Y TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS

Abstract

The Hospital at Home (HaH) model has been positioned as an appropriate therapeutic strategy for selected patients undergoing autologous hematopoietic stem cell transplantation (ASCT). This care model provides hospital-equivalent care, in terms of both quality and quantity, with medical and nursing staff that go to the patient's home. Here we describe our experience with a full HaH model for patients undergoing ASCT during the phase of aplasia. The patients met the eligibility criteria between January 1997 and December 2019 and were discharged from the hospital and admitted into the HaH-ASCT program on the same day they in which hematopoietic stem cells were infused. A total of 84 patients were included. The median patient age was 54 years (range, 16 to 74 years), and the median duration of participation in the HaH program was 17 days (range, 3 to 86 days). Only 10 of these patients (12%) required hospi-tal readmission to the hematology department, 9 of them due to sepsis and 1 because of family care support claudica-tion. Seventy-two patients (86%) experienced an episode of neutropenic fever during the HAH admission, with a median duration of 2 days (interquartile range [IQR], 1 to 11 days); all were treated with empiric i.v. antimicrobial therapy. Most patients (88%) presented with mucositis (44% with grade 3-4). Parenteral nutrition was administered in 26% of patients for a median of 6 days (IQR, 1 to 12 days). Most patients (94%) required at least 1 blood product trans-fusion at home. There was no transplantation-related mortality during the HaH-ASCT program or in the patients who were readmitted. With careful selection of patients and a comprehensive and well-experienced multidisciplinary team (doctors, nurses, and auxiliary nurses) in the HaH department and in close collaboration with the hematology department, complete at-home management of ASCT recipients immediately after transplantation is possible. This allows patients undergoing an aggressive procedure such as ASCT to remain in their own familiar environment, pro-viding a better quality of life with a program that has demonstrated to be effective and safe, with a low incidence of complications and no associated mortality. (C) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Keywords

• Autologous stem cell transplantation; Hospital at Home; Hospital readmission; Outpatient